Gilead’s twice-yearly shot cut HIV infections by 96% in trial

Gilead’s twice-yearly shot cut HIV infections by 96% in trial

Submitted by admin on September 12, 2024 - 10:28am
Source: 
CNBC
News Tags: 
Gilead Sciences
HIV
lenacapavir
Headline: 
Gilead’s twice-yearly shot cut HIV infections by 96% in trial
snippet: 
  • Gilead’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday.
  • The data sets the stage for likely FDA approval of Lenacapavir for HIV prevention.
  • Shares rose 3% in premarket trading.

Do Not Allow Advertisers to Use My Personal information